1. Home
  2. FHI vs FOLD Comparison

FHI vs FOLD Comparison

Compare FHI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Federated Hermes Inc.

FHI

Federated Hermes Inc.

HOLD

Current Price

$56.23

Market Cap

4.1B

Sector

Finance

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.49

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FHI
FOLD
Founded
1955
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.5B
IPO Year
1998
2006

Fundamental Metrics

Financial Performance
Metric
FHI
FOLD
Price
$56.23
$14.49
Analyst Decision
Hold
Buy
Analyst Count
5
9
Target Price
$54.20
$27.25
AVG Volume (30 Days)
705.0K
2.5M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.41%
N/A
EPS Growth
58.82
50.00
EPS
1.27
N/A
Revenue
$1,102,924,000.00
N/A
Revenue This Year
$9.90
$20.50
Revenue Next Year
$4.35
$18.59
P/E Ratio
$43.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$41.55
$5.66
52 Week High
$59.05
$14.50

Technical Indicators

Market Signals
Indicator
FHI
FOLD
Relative Strength Index (RSI) 53.08 74.18
Support Level $51.62 $14.21
Resistance Level $57.35 N/A
Average True Range (ATR) 1.45 0.02
MACD 0.21 -0.00
Stochastic Oscillator 76.98 100.00

Price Performance

Historical Comparison
FHI
FOLD

About FHI Federated Hermes Inc.

Federated Hermes provides asset management services for institutional and individual investors. The firm had $902.6 billion in managed assets at the end of 2025, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (76%) funds. The firm's cash management operations are expected to generate around 55% of Federated's revenue this year, compared with 27%, 10%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (68% of AUM), institutional investors (25%), and international clients (7%).

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: